Authors
Eric Y. Stutheit-Zhao; Enrique Sanz-Garcia; Zhihui (Amy) Liu; Derek Wong; Kayla Marsh; Albiruni R. Abdul Razak; Anna Spreafico; Philippe L. Bedard; Aaron R. Hansen; Stephanie Lheureux; Dax Torti; Bernard Lam; Shih Yu Cindy Yang; Justin Burgener; Ping Luo; Yong Zeng; Nicholas Cheng; Philip Awadalla; Scott V. Bratman; Pamela S. Ohashi; Trevor J. Pugh; Lillian L. Siu
Abstract
Early kinetics of circulating tumor DNA (ctDNA) in plasma predict response to pembrolizumab but typically requires sequencing of matched tumor tissue or fixed gene panels. We analyzed genome-wide methylation and fragment-length profiles using cell-free methylated DNA immunoprecipitation and sequencing (cfMeDIP-seq) in 204 plasma samples from 87 patients before and during treatment with pembrolizumab from a pan-cancer phase II investigator-initiated trial (INSPIRE). We trained a pan-cancer methylation signature using independent methylation array data from The Cancer Genome Atlas to quantify cancer-specific methylation (CSM) and fragment-length score (FLS) for each sample. CSM and FLS are strongly correlated with tumor-informed ctDNA levels. Early kinetics of CSM predict overall survival and progression-free survival, independently of tumor type, PD-L1, and tumor mutation burden. Early kinetics of FLS are associated with overall survival independently of CSM. Our tumor-naïve mutation-agnostic ctDNA approach integrating methylomics and fragmentomics could predict outcomes in patients treated with pembrolizumab.
Significance:
Analysis of methylation and fragment length in plasma using cfMeDIP-seq provides a tumor-naive approach to measure ctDNA with results comparable with a tumor-informed bespoke ctDNA. Early kinetics within the first weeks of treatment in methylation and fragment quantity can predict outcomes with pembrolizumab in patients with various advanced solid tumors.
Read morePosted on: